Vamorolone
New Drug Approvals
JULY 25, 2025
Syn EuropeanJournalofMedicinalChemistry265(2024)116124 Vamorolone (Agamree) On October 26, 2023, Vamorolone, developed jointly by Santhera Pharmaceuticals and ReveraGen BioPharma, has received FDA approval to treat DMD in patients aged 2 years and older [1]. September 2016). 23] Vamorolone is sold under the brand name Agamree.
Let's personalize your content